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Abstract
Objective To investigate the responsiveness of and corre-
lation between the EQ-5D-5L and the QOLIE-31P in
patients with epilepsy, and develop a mapping function to
predict EQ-5D-5L values based on the QOLIE-31P for use
in economic evaluations.
Methods The dataset was derived from two clinical trials,
the ZMILE study in the Netherlands and the SMILE study
in the UK. In both studies, patients’ quality of life using the
EQ-5D-5L and QOLIE-31P was measured at baseline and
12 months follow-up. Spearman’s correlations, effect sizes
(EF) and standardized response means (SRM) were cal-
culated for both the EQ-5D-5L and QOLIE-31P domains
and sub scores. Mapping functions were derived using
ordinary least square (OLS) and censored least absolute
deviations models.
Results A total of 509 patients were included in this study.
Low to moderately strong significant correlations were
found between both instruments. The EQ-5D-5L showed
high ceiling effects and small EFs and SRMs, whereas the
QOLIE-31P did not show ceiling effects and also showed
small to moderate EFs and SRMs. Results of the different
mapping functions indicate that the highest adjusted R2 we
were able to regress was 0.265 using an OLS model with
squared terms, leading to a mean absolute error of 0.103.
Conclusions Results presented in this study emphasize the
shortcomings of the EQ-5D-5L in epilepsy and the
importance of the development of condition-specific pref-
erence-based instruments which can be used within the
QALY framework. In addition, the usefulness of the con-
structed mapping function in economic evaluations is
questionable.
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Introduction
Epilepsy is a disorder of the brain, characterized by
recurrent seizures. Seizure episodes are a result of exces-
sive electrical discharges in a group of brain cells. Dif-
ferent parts of the brain can be the site of such discharges.
These discharges result in a variety of clinical manifesta-
tions, depending on where they occur in the brain. The
clinical manifestations can vary from the briefest lapses of
attention or muscle jerks to severe and prolonged convul-
sions [1].
In economic evaluation, both in general and in the field
of epilepsy, the quality adjusted life year (QALY) is rou-
tinely used as a summary measure of health outcome for
economic evaluations, which incorporates the impact on
both the quantity and quality of life (QoL). For example,
the use of QALYs is required by the National Institute for
Health and Clinical Excellence (NICE) in England and
Wales [2] and the Healthcare institute in the Netherlands
[3] for an intervention to be reimbursed. The utility part of
QALYs requires health state values as QALYs are calcu-
lated based on the time spent in a specific health state
multiplied by the corresponding utility of that health state.
Commonly used measures to include in the QALYs are
generic utility measures, such as the EuroQol 5 dimensions
5 levels (EQ-5D-5L) [4, 5], Short Form 6 dimensions (SF-
6D) [6] and the Health Utility Index (HUI) [7]. Generic
utility instruments are designed to be applicable in a large
variety of conditions.
However, there are instances, especially in clinical
research, where some generic utility measures fail to cap-
ture changes that, even if small, are important to patients.
Some studies use condition-specific or condition-specific
utility measures to address this limitation. It is suggested
that these instruments are likely to be more responsive than
generic instruments, whose strengths include breadth and
applicability across conditions and interventions [8]. The
responsiveness of an instrument is likely to be dependent
on several factors such as the nature of the condition and
the domains included in the instrument. For example, the
EuroQol-5D-3L (i.e. a generic utility instrument) has been
demonstrated to correlate in a moderately to good way with
criterion measures in patients with chronic low back pain
[9]. In contrast, the EQ-5D-3L was deemed unsuitable for
people with dementia, leading to the development of a
condition-specific questionnaire (DEMQOL) [10]. In epi-
lepsy, the EQ-5D-3L has been shown to correlate well with
another generic quality of life instrument, the 15D-instru-
ment [11]. However, in patients with newly diagnosed
focal epilepsy, the EuroQol-5D-3L was compared to an
epilepsy-specific instrument (NEWQOL-6D) and was
shown to be less responsive than the NEWQOL-6D [12].
Selai et al. [13] examined the use of the EQ-5D-3L in
people with epilepsy and concluded that adaptation, sei-
zures, and the stigma of epilepsy considerably impair
quality of life but are not captured using the EQ-5D-3L,
which limit its applicability [13].
Wiebe et al. [8] evaluated 43 randomized controlled
trials which used generic and specific QoL instruments and
concluded that specific instruments are more responsive
than generic tools. Furthermore, they stress that investi-
gators may come to misleading conclusions by using
generic instruments. However, condition-specific measures
lack cross-program comparability. Furthermore, if a con-
dition-specific quality of life instrument were used for the
calculation of QALYs, the valuation set should be con-
structed according to the same principles as generic utility
measures (i.e. the multi attribute utility theory [14]), which
is often not the case. An alternative option would be to
derive well-conducted and validated mapping functions to
map condition-specific outcomes to generic utilities. A
mapping function is a regression equation used to predict
values of, in this case, a generic utility instrument, using
scores/values from a condition-specific instrument as
regressors (also known as ‘cross-walking’) [15]. Albeit not
resolving issues regarding insensitivity of generic instru-
ments, mapping is a solution which enables health state
utilities to be predicted when no preference-based measure
has been included in the study [15, 16]. Such mapping
functions are supposed to yield utility values comparable
generic instruments [16]. However, the performance of a
mapping function is dependent on and requires a degree of
overlap between both measures and that the two measures
are administered on the same population [15, 17]. The aim
of this study is to compare the EQ-5D-5L and an often used
condition-specific QoL instrument, the Quality of Life in
Epilepsy-Patients-Weighted 31p (QOLIE-31P) [18]. The
objective of this study is to investigate the correlation
between and the responsiveness of the EQ-5D-5L and the
QOLIE-31P in patients with epilepsy. In addition, we aim
to develop a mapping function to predict EQ-5D-5L values
based on the QOLIE-31P for use in economic evaluations.
Methods
QOLIE-31p
The QOLIE-31-P is a condition-specific QoL instrument
which consists of 38 items assessing 7 domains of epilepsy:
seizure worry, overall QOL, emotional well-being, energy-
fatigue, cognitive functioning including memory,
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medication effects, social functioning and an overall score.
In addition, for each domain, questions regarding how
much distress a person feels about problems and worries
related to epilepsy are included. Each domain is scored on
a scale ranging from 0 to 100. Afterwards a final score can
be calculated using weights derived from the amount of
distress related to each domain. The final score ranges from
0 to 100, in which higher values indicate a better QoL [19].
EQ-5D-5L
The EQ-5D-5L is generally used as a generic QoL instru-
ment which consists of five dimensions: mobility, self-care,
usual activities, pain/discomfort, anxiety/depression, each
of which can have one of five responses [4, 5] (e.g. no pain,
slight pain, moderate pain, severe pain and extreme pain).
This measure produces a possible 3125 distinct health
states ranging from 11111 (full health) to 55555 (worst).
The EQ-5D-5L was valued using both the Dutch and the
UK tariffs [5, 20, 21].
Data set
The SMILE study data [22, 23] and the ZMILE study data
[24] were used for the analyses. Both studies examined the
(cost-) effectiveness of a self-management program for
patients with epilepsy. Follow-up data was available for
12 months in both studies. Inclusion criteria for both
studies were similar (i.e. epilepsy diagnosis, prescribed
antiepileptic drugs, no severe psychiatric disorders, being
able to participate and benefit from group sessions).
However, the SMILE study included patients from age
C16 years whereas the ZMILE study included patients
aged C18 years, and patients in the SMILE group were
also screened to have had at least two seizures in the
12 months before inclusion. Patients with complete data
for each of the measures across each time point were
included.
For the direct response mapping, the data set was ran-
domly split (using the ‘‘approximately 50% of the cases’’
function in SPSS) into two separate data sets: (1) the
‘‘estimation sample’’ (N = 283), which was used to derive
the mapping functions; (2) the ‘‘validation sample’’
(N = 224) which was used to validate the mapping
functions.
Responsiveness analyses
Descriptive analyses are presented for patient characteris-
tics. To measure concurrent validity (i.e. the strength of the
relationship between measures of the same concept)
Spearman’s correlation was calculated between the
domains and total scores (i.e. utilities) of the EQ-5D-5L
and the QOLIE-31P. Spearman’s correlation was used due
to the skewed nature of the data, especially EQ-5D-5L
utilities. Strong correlations indicate that the preference-
based measures are assessing related constructs. Correla-
tions are considered weak if scores are less than 0.3,
moderate if scores are between 0.3 and less than 0.7, and
strong if scores are 0.7 or higher [25]. Bonferroni correc-
tion was applied to account for multiple testing (i.e.
adjustment of p-values) [26].
To determine the predictive validity or responsiveness of
both instruments (i.e. the ability of an instrument to detect
relevant changes in QoL over time) the standardized
response mean (SRM) and effect size (EF) were calculated.
The SRM is a standard indicator of change across measures
and time points and was calculated by SRM = (M1 - M2)/
(SD1 - SD2), where M1 is the mean pre-assessment and
M2 is the mean post-assessment, and SD1 and SD2 are the
standard deviations of both assessments [25]. SRMs of less
than 0.2 are considered small, 0.5 moderate, and 0.8 large
[25, 27]. The EF is calculated as the difference between
follow-up and baseline divided by the standard deviation of
the group’s baseline scores. The SRM and EF were calcu-
lated for those patients amongst whom a change in health
state was observed between baseline and follow-up. Floor
and ceiling effects were examined. For each questionnaire
the proportion of respondents with a minimum score (re-
ferred to as ‘floor effects’) or a maximum score (referred to as
‘ceiling effects’) was calculated. If a large proportion of the
population is at the floor (lowest possible score) or ceiling
(highest possible score), then this impairs the ability of the
measure to pick up decreases or increases in QoL, respec-
tively [12]. The EF and the SRM are the most common
measures for responsiveness. Positive values reflect (stan-
dardized) improvements in the number of standard devia-
tions of the baseline scores (EF) or the score differences
(SRM) (i.e. unit-free) [28].
Mapping approach
To estimate EQ-5D-5L utilities based on the QOLIE-31P,
direct response mapping was used to regress QOLIE-31P
scores to EQ-5D-5L utilities. In direct mapping, a regres-
sion equation is used to predict the values of the EQ-5D-5L
using scores/values from the QOLIE-31P as regressors.
Next, the coefficients of the model are used to carry out the
conversion from the source measure to the target measure
in the required dataset [29]. Spearman’s correlations of the
independent variables were used to determine whether
there was collinearity between independent variables,
which would then be removed from the analyses. A
collinearity threshold of[0.70 was used [30].
Ordinary least-squares (OLS) and censored least abso-
lute deviations (CLAD) regression was used to estimate the
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model. The OLS is the most commonly used model in
mapping studies [15, 31]. However, it is unable to restrict
for the range of values and may lead to implausible pre-
dicted values (e.g. EQ-5D values above 1). The CLAD
model was therefore used as it has the ability to account for
censored or bounded data. In addition, it is robust to
heteroscedasticity and can also be used for skewed data
[15, 32].
As the aim of this study was to derive a predictive
model, all items (domains) were included in the model
despite their significance level, which is often considered
best practice [33–35].
Furthermore, no attempt was made to predict the indi-
vidual EQ-5D-5L dimensions separately as this has been
shown to be a less efficient strategy or to give similar
results in terms of prediction [36].
For both the OLS and the CLAD model, specifications
of the mapping functions were constructed as proposed by
Brazier et al. (2010) [15]. We started with a simple additive
model by predicting EQ-5D values from the total QOLIE-
31P scores including age, gender, employment, and living
arrangements (model 1). Next, the EQ-5D-5L values were
predicted from the 7 QOLIE-31P dimension sub scores
(model 2). To relax the assumptions of the simple additive
model, squared terms for dimension sub scores were
included in the model (model 3) [15]. As suggested by
Brazier et al. (2010) only significant squared terms were
included in the model to reduce the number of variables
[15].
The predictive validity of the mapping models was
assessed by using: (1) the goodness of fit as assessed using
adjusted/pseudo R-squared (OLS and CLAD) in the esti-
mation sample; and (2) the predictive performance of the
models in the validation sample was assessed using the
mean absolute error (MAE).
All analyses were done in STATA 15 (StataCorp, Col-
lege Station, TX, USA).
Results
The dataset consisted of 509 patients of which 102 patients
were recruited for the ZMILE study and 407 for the SMILE
study. In total, 53.0% of the patients were female and the
majority of the patients were aged between 25 and 44 years
old. Most of the patients had a household or lived with
others (73.1%) and 51.3% of the patients were unem-
ployed. Mean quality of life according to the EQ-5D-5L
was 0.86 and mean condition-specific quality of life
according to the QOLIE-31P was 65.82. More detail
regarding the characteristics of the population(s) is repor-
ted in Table 1.
Validity and responsiveness
An assessment of the strength of the relationship between
the EQ-5D-5L and the QOLIE-31P based on Spearman’s
correlation coefficient, showed moderately strong signifi-
cant correlations between both instruments for the total
score (Table 2). Only a few statistically significant corre-
lations were found between the sub scores of the QOLIE-
31P and the sub scores of the EQ-5D-5L. All sub scores of
the QOLIE-31P did significantly correlate with the total
EQ-5D-5L scores. At baseline and 12 months follow-up
ceiling effects on the EQ-5D-5L were substantial with 37.8
and 33.5% of the patients reporting the maximum score.
No ceiling effects were found for the QOLIE-31P.
Details regarding the EF and SRM are presented in
Table 3. EFs and SRMs all appear to be relatively small.
Both the EF and SRM estimates are smaller for the EQ-5D-
5L than the QOLIE-31P. For the EQ-5D-5L, values range
from -0.017 to 0.043 for the EF and from -0.023 to 0.025
for the SRM which would be considered small. The EF and
SRM values for the QOLIE-31P range from 0.082 to 0.290
(EF) and from 0.07 to 0.270 (SRM), which would be
regarded as small to moderate.
Mapping functions
The EQ-5D index scores had a somewhat bimodal distri-
bution, and the distribution of the QOLIE-31P index scores
were normally distributed (see Online Supplementary
Materials 1). The inclusion of age was shown to have a
significant effect on the prediction of EQ-5D-5L scores. All
other demographic variables were excluded from the
analyses. In addition, there was a significant effect asso-
ciated with country (i.e. SMILE or ZMILE dataset). Hence,
age and country were included in all mapping functions.
For the OLS mapping functions, model 3 performed best
with an MAE of 0.103 and an adjusted R2 of 0.265.
Inclusion of age significantly improved the model, hence a
model without age was only constructed for OLS. For the
CLAD mapping functions, CLAD model 3 performed best
with a MAE of 0.097 and a pseudo R2 of 0.160. It should be
noted, however, that including squared terms only
improved adjusted/pseudo R2 values and only marginally
improved MAE in the estimation sample (see Table 4). All
models predicted values above 1 (full health), of which
OLS model 2 was closest to 1 with maximum values of
1.020. A graphical representation of the model fits is pre-
sented in Fig. 1.
When assessing the MAE in the validation sample, using
the mapping functions derived from the estimation sample,
OLS model 1 performed best with a MAE of 0.114.
Likewise, for the CLAD mapping functions, model 1 per-
formed best with a MAE value of 0.109 (see Table 5).
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Given the higher adjusted/pseudo R2 values of model 3
compared to model 1 for both OLS and CLAD, and given
the lower MAE for OLS model 3 compared to CLAD
model 3 in the validation sample, the best mapping func-
tion would be OLS model 3. The regression coefficients
for this model are presented in Online Supplementary
Materials 1.
Discussion
The aim of this study was to compare the responsiveness of
the QOLIE-31P and the EQ-5D-5L in epilepsy and to
predict EQ-5D-5L values based on QOLIE-31P scores with
the development of a mapping function. Looking at con-
current validity, although the correlations were significant,
Table 1 (Baseline)
characteristics of the population
Characteristics ZMILE sample SMILE sample Total
(n = 102) (n = 407) (n = 509)
Gender
Male 50 (49.0%) 185 (45.5%) 235 (46.2%)
Female 52 (51.0%) 219 (53.8%) 271 (53.2%)
Missing values 0 3
Age in years
16–24 17 (16.7%) 46 (11.3%) 63 (12.4%)
25–44 42 (41.2%) 194 (47.7%) 236 (46.4%)
45–64 37 (36.2%) 142 (34.9%) 179 (35.2%)
C65 6 (5.9%) 22 (5.4%) 28 (5.5%)
Missing values 0 3
Living arrangements, n (%)
Household/living with others 67 (65.7%) 305 (74.9%) 372 (73.1%)
Living alone 26 (25.5%) 95 (23.4%) 121 (23.8%)
Other arrangements 4 (3.9%) 4 (1%) 8 (1.6%)
Missing values 5 3
Employment
Not unemployed 54 (52.9%) 207 (50.9%) 261 (51.3%)
Specifically employed or student 44 (43.1%) 197 (48.4%) 241 (47.4%)
Missing values 4 3
Quality of life
EQ-5D-5L baseline 0.83 0.87 0.86
EQ VAS 74.77 67.00 68.53
QOLIE-31P baseline 64.74 66.05 65.82
Table 2 Spearman’s correlation coefficients between QOLIE-31P values and EQ-5D-5L values
EQ-5D
mobility
EQ-5D self-
care
EQ-5D usual
activities
EQ-5D
pain
EQ-5D anxiety and
depression
Total EQ-5D
score
QOLIE-31P energy -0.2330 -0.1896 -0.1991 -0.2689* -0.2293 0.4499*
QOLIE-31P mood -0.1252 -0.0285 -0.1725 -0.1743 -0.3823* 0.4881*
QOLIE-31P daily activities -0.2350 -0.2138 -0.2557* -0.2644* -0.2422* 0.4335*
QOLIE-31P cognition -0.1041 -0.0607 -0.1906 -0.1661 -0.2539* 0.2948*
QOLIE-31P medication
effects
-0.0569 -0.1061 -0.1744 -0.1969 -0.2304 0.2730*
QOLIE-31P seizure worry -0.1099 -0.0802 -0.1502 -0.1901 -0.3057* 0.3906*
QOLIE-31P overall QOL -0.1794 -0.1620 -0.2245 -0.1808 -0.3142* 0.4049*
Total QOLIE-31P score -0.2000 -0.1476 -0.2855* -0.3171* -0.3354* 0.5653*
* Significant correlation at 5% level
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the strength was only moderate between both instruments
when looking at the total score. This may imply that both
instruments are only measuring the same concept to some
extent and impose conceptual differences.
The EQ-5D-5L showed substantially high ceiling effects
and was demonstrated to have rather small EFs and SRMs,
whereas the QOLIE-31P did not show ceiling effects and
had small to moderate EFs and SRMs. This indicates that
the QOLIE-31P has an overall higher responsiveness based
on EF, SRM and ceiling effects. Furthermore, this study
provides a mapping function which can be used in (future)
economic evaluations to map QOLIE-31P data to EQ-5D-
5L values.
The relatively small EFs and SRMs may be explained by
a lack of responsiveness of both instruments, especially the
EQ-5D-5L. However, part of these small estimates can be
explained by the fact that the patients’ health state did not
change much over time. The EF and SRM were calculated
in all patients who had any change during follow-up, due to
the lack of a known clinically meaningful difference for
both instruments; this led to an underestimation of the EF
and SRM. The EQ-5D-5L, however, performed substan-
tially worse than the QOLIE-31P (i.e. lower estimated EFs
and SRMs).
Using different mapping functions, the highest adjusted
R2 we were able to regress was 0.265 using an OLS model
Table 3 Standardized response
means for QOLIE-31P and EQ-
5D-5L
Mean difference between
BS and FU12M
Effect size Standardized
response mean
Total EQ-5D-5L score -0.004 -0.017 -0.023
EQ-5D mobility 0.276 0.010 0.003
EQ-5D self-care 0.305 0.010 0.003
EQ-5D usual activities 2.600 0.043 0.025
EQ-5D pain 0.619 0.012 0.006
EQ-5D anxiety -1.847 -0.017 -0.019
Total QOLIE-31P score 2.414 0.187 0.212
QOLIE-31P energy 1.875 0.110 0.080
QOLIE-31P mood 1.906 0.082 0.070
QOLIE-31P daily activities 8.317 0.284 0.270
QOLIE-31P cognition 3.196 0.131 0.125
QOLIE-31P medication effects 5.878 0.177 0.178
QOLIE-31P seizure worry 7.696 0.290 0.254
QOLIE-31P overall QOL 2.963 0.128 0.116
EQ-5D-5L EuroQol 5 dimensions with 5 levels, BS baseline, FU12M follow-up measurement at 12 months
Table 4 Summary of observed and predicted values for all models in estimation dataset (N = 283)
Observed EQ-
5D utility
Predicted EQ-5D utilities
Total QOLIE-
31P scores
Total QOLIE-31P and
age and country
QOLIE-31P domain scores
and age and country
Domain scores and squared terms
and age and country
OLS model 0 OLS model 1 OLS model 2 OLS model 3
Mean 0.867 0.868 0.868 0.871 0.872
Minimum 0.055 0.668 0.673 0.690 0.647
Maximum 1.000 1.026 1.020 1.082 1.086
MAE 0.110 0.107 0.103 0.103
Adjusted
R2
0.151 0.180 0.211 0.265
CLAD model 1 CLAD model 2 CLAD model 3
Mean 0.867 – 0.915 0.916 0.920
Minimum 0.055 – 0.711 0.697 0.698
Maximum 1.000 – 1.072 1.15 1.119
MAE – 0.099 0.099 0.097
Pseudo R2 – 0.116 0.129 0.160
MAE mean absolute error, OLS ordinary least squares, CLAD censored least absolute deviations
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with squared terms, which led to a MAE of 0.103. Overall,
this model performed best given the results within the
estimation and validation sample. Although theoretically
preferred, the use of a CLAD model did not perform better
than the OLS model, especially in the validation sample.
Mixed results have been reported in studies using CLAD
models [17], with some concluding that CLAD improved
the model fit [37, 38] and others concluding that the
improvement of CLAD over OLS was small or did not
have an impact [39]. The adjusted/pseudo R2 values found
in this study were relatively small, which is not uncommon.
In a review of Brazier et al. (2010), it was found that
models mapping a generic instrument onto a generic
preference-based measure achieved an adjusted R2 of more
than 0.5 within sample. However, in studies examining the
fit of functions mapping from condition-specific to generic
measures, results were more variable ranging from 0.17 to
0.51 [15]. In addition, errors were often larger for models
Fig. 1 Scatter plots comparing observed vs predicted EQ-5D-5L values for OLS (a–c), CLAD (d–f)
Table 5 Summary of observed and predicted values for all models in validation dataset (N = 224)
Observed EQ-5D
utility
Predicted EQ-5D utilities
Total QOLIE-31P and age
and country
QOLIE-31P domain scores and age
and country
Domain scores and squared terms and
age and country
OLS model 1 OLS model 2 OLS model 3
Mean 0.863 0.865 0.865 0.865
Minimum 0.054 0.649 0.685 0.629
Maximum 1.000 1.039 1.100 1.084
MAE 0.114 0.116 0.118
CLAD model 1 CLAD model 2 CLAD model 3
Mean 0.863 0.912 0.907 0.911
Minimum 0.054 0.682 0.688 0.699
Maximum 1.000 1.062 1.136 1.120
MAE 0.109 0.117 0.119
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mapping a generic measure onto a generic preference-
based measure [15, 17]. Likewise, the usefulness of our
mapping function in economic evaluations is questionable
given the relatively large mean absolute error and poor
model fit.
Another way of mapping would be to use a model to
predict responses of each of the five dimensions of the EQ-
5D-5L from the QOLIE-31P (sub) scores; so-called indi-
rect response mapping or response mapping models [40].
As the purpose of the mapping part of this study was to
derive a regression function, this method was not applied.
In addition, as mentioned above, indirect response mapping
has been shown to be a less efficient strategy or to give
similar results in terms of prediction [36].
The use of mapping to derive EQ-5D-5L values is
fundamentally limited by the degree of overlap between
two instruments [17]. Although several studies reported
limitations with generic preference-based quality of life
instruments regarding their responsiveness and ability to
discriminate between health states (e.g. McTaggart-Cowan
et al. [41]), the use of generic preference-based instruments
is mandatory in most national guidelines for pharma-
coeconomic evaluations, for example in the UK and the
Netherlands [3, 42]. However, given the limited respon-
siveness, low correlations, and the poor model fit of the
mapping functions it may be argued that there is a need for
the development of condition-specific preference-based
measures for patients with epilepsy. General (non-prefer-
ence based) condition-specific instruments, such as the
QOLIE-31P, are an important source of evidence; however,
their use in economic evaluation is severely limited
because they were not designed for this purpose and, unless
they are preference-based, they theoretically cannot be
used to calculate quality adjusted life years (QALYs)
[14, 43]. Several attempts have been made to derive con-
dition-specific quality of life instruments to calculate
(condition-specific) QALYs, such as the development of
new instruments [44, 45] or the development of condition-
specific preference-based measures from existing instru-
ments [46, 47]. Of course, such a measure could not be the
sole outcome of interest for economic evaluations, as they
lack the comparability between conditions, a distinct
advantage of generic instruments [48]. We agree with
Brazier et al. (2010), that development of a condition-
specific preference-based instrument should not be seen as
an alternative to generic preference-based measures, but
rather as a supplement [43]. Condition-specific preference-
based instruments may have an important role in ensuring
that the benefits of health-care interventions are adequately
reflected in QALY estimates for economic evaluations in
all conditions [49].
This study is subject to several limitations. First, we
only investigated the use of a few mapping models,
whereas a wide variety of models exist, such as GLM or
Tobit models. Furthermore, other correlation coefficients
may have been used, such as polychoric correlation coef-
ficients. However, given the marginal differences between
the models used in this study, the model fit is not likely to
be improved substantially. In addition, structural equation
modelling could be used to analyze the structural rela-
tionship between EQ-5D-5L and QOLIE-31P and latent
constructs. Second, our estimations are based on a pooled
data set containing data from both the UK and the
Netherlands. Although inclusion criteria for both studies
were similar and there was no significant difference
between the countries regarding regression estimates, this
may have introduced extra heterogeneity within the data.
Lastly, the pooled dataset was divided into an estimation
sample and a validation sample. This has the advantage
that it assesses the mapping function by its prime purpose;
however, it reduces the sample size of the estimation
sample. The use of the whole sample for the model esti-
mations, however, did not substantially improve the
model(s).
Conclusion
There was a low to moderate correlation between the sub
scores and total scores of the EQ-5D-5L and the QOLIE-
31P. Both the EF and SMRs were relatively low, especially
for the EQ-5D-5L. Mapping functions to regress QOLIE-
31P values to EQ-5D-5L values did not show an optimal fit
with relatively low adjusted R2 values. The results pre-
sented in this study may emphasize the importance of the
development of condition-specific preference-based
instruments which can be used within the QALY frame-
work and hence be incorporated as an important supple-
ment in economic evaluations. The development of such
condition-specific preference-based quality of instruments
can ensure that the benefits of health-care interventions are
adequately reflected in QALY estimates for economic
evaluations not only in epilepsy but for all conditions.
Acknowledgements The views and opinions expressed are those of
the authors and do not necessarily reflect those of the HTA pro-
gramme, the UK NIHR, NHS or the Department of Health. We would
like to thank Dr. M. Dzingina (King’s College London) for his help
with the analyses of the results.
Compliance with ethical standards
Funding This study was funded by the Netherlands Organization for
Health Research and Development (ZonMw), Grant application no.
836011018. Data collection in the SMILE trial was funded by the
National Institute for Health Research [Health Technology Assess-
ment (HTA) programme] (Project no. 09/165/01).
B. F. M. Wijnen et al.
123
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. World Health Organization. Epilepsy. (2016). http://www.who.
int/mediacentre/factsheets/fs999/en/
2. Whitehead, S.J., Ali, S.: Health outcomes in economic evalua-
tion: the QALY and utilities. Br. Med. Bull. 96(1), 5–21 (2010).
doi:10.1093/bmb/ldq033
3. Nederland, Z.: Richtlijn voor het uitvoeren van economische
evaluaties in de gezondheidszorg. Zorginstituut Nederland, Die-
men (2015)
4. Brooks, R.: EuroQol: the current state of play. Health policy
(Amsterdam, Netherlands). 37(1), 53–72 (1996)
5. Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing
health-related quality of life: an EQ-5D-5L value set for England
(2016)
6. Brazier, J., Roberts, J., Deverill, M.: The estimation of a pref-
erence-based measure of health from the SF-36. J. Health Econ.
21(2), 271–292 (2002). doi:10.1016/S0167-6296(01)00130-8
7. Horsman, J., Furlong, W., Feeny, D., Torrance, G.: The health
utilities index (HUI()): concepts, measurement properties and
applications. Health Qual. Life Outcomes. 1, 54 (2003). doi:10.
1186/1477-7525-1-54
8. Wiebe, S., Guyatt, G., Weaver, B., Matijevic, S., Sidwell, C.:
Comparative responsiveness of generic and specific quality-of-
life instruments. J. Clin. Epidemiol. 56(1), 52–60 (2003)
9. Soer, R., Reneman, M.F., Speijer, B.L., Coppes, M.H., Vroomen,
P.C.: Clinimetric properties of the EuroQol-5D in patients with
chronic low back pain. Spine J. Off. J. North Am. Spine Soc.
12(11), 1035–1039 (2012). doi:10.1016/j.spinee.2012.10.030
10. Smith, S.C., Lamping, D.L., Banerjee, S., Harwood, R., Foley, B.,
Smith, P. et al.: Measurement of health-related quality of life for
people with dementia: development of a new instrument (DEM-
QOL) and an evaluation of current methodology. Health Technol.
Assess. (Winchester, England). 9(10), 1–93, iii–iv (2005)
11. Stavem, K., Bjørnæs, H., Lossius, M.I.: Properties of the 15D and
EQ-5D utility measures in a community sample of people with
epilepsy. Epilepsy Res. 44(2–3), 179–189 (2001). doi:10.1016/
S0920-1211(01)00201-7
12. Mulhern, B., Pink, J., Rowen, D., Borghs, S., Butt, T., Hughes,
D., et al.: Comparing generic and condition-specific preference-
based measures in epilepsy: EQ-5D-3L and NEWQOL-6D. Val.
Health. (2016). doi:10.1016/j.jval.2016.03.1860
13. Selai, C.E., Elstner, K., Trimble, M.R.: Quality of life pre and
post epilepsy surgery. Epilepsy Res. 38(1), 67–74 (2000)
14. Von Neumann, J., Morgenstern, O.: Theory of games and eco-
nomic behavior. Princeton university press, Princeton (2007)
15. Brazier, J.E., Yang, Y., Tsuchiya, A., Rowen, D.L.: A review of
studies mapping (or cross walking) non-preference based mea-
sures of health to generic preference-based measures. Eur.
J. Health Econ. 11(2), 215–225 (2010). doi:10.1007/s10198-009-
0168-z
16. Versteegh, M.M., Leunis, A., Uyl-de Groot, C.A., Stolk, E.A.:
Condition-specific preference-based measures: benefit or burden?
Val. Health. 15(3), 504–513 (2012)
17. Longworth, L., Rowen, D.: Mapping to obtain EQ-5D utility
values for use in NICE health technology assessments. Val.
Health J. Int. Soc. Pharmacoecon. Outcomes Res. 16(1), 202–210
(2013). doi:10.1016/j.jval.2012.10.010
18. Cramer, J.A., Perrine, K., Devinsky, O., Bryant-Comstock, L.,
Meador, K., Hermann, B.: Development and cross-cultural
translations of a 31-item quality of life in epilepsy inventory.
Epilepsia. 39(1), 81–88 (1998)
19. Cramer, J.A., Van Hammee, G.: Maintenance of improvement in
health-related quality of life during long-term treatment with
levetiracetam. Epilepsy Behav. E&B. 4(2), 118–123 (2003)
20. Versteegh, M.M., Vermeulen, K.M., Evers, S.M.A.A., de Wit,
G.A., Prenger, R., Stolk, E.A.: Dutch tariff for the five-level
version of EQ-5D. Val. Health. 19(4), 343–352 (2016). doi:10.
1016/j.jval.2016.01.003
21. Feng, Y., Devlin, N., Koonal, S., Brendan, M., van Hout, B.: New
methods for modelling EQ-5D-5L value sets: an application to
English data. Office of Health Economics Research (2016)
22. Kralj-Hans, I., Goldstein, L.H., Noble, A.J., Landau, S., Magill,
N., McCrone, P., et al.: Self-management education for adults
with poorly controlled epilepsy (SMILE (UK)): a randomised
controlled trial protocol. BMC Neurol. 14, 69 (2014). doi:10.
1186/1471-2377-14-69
23. Magill, N., Ridsdale, L., Goldstein, L.H., McCrone, P., Morgan,
M., Noble, A.J., et al.: Self-management education for adults with
poorly controlled epilepsy (SMILE (UK)): statistical, economic
and qualitative analysis plan for a randomised controlled trial.
Trials. 16, 269 (2015). doi:10.1186/s13063-015-0788-9
24. Leenen, L.A., Wijnen, B.F., de Kinderen, R.J., Majoie, M.H., van
Heugten, C.M., Evers, S.M.: Cost-effectiveness of a multi-com-
ponent intervention for adults with epilepsy: study protocol of a
Dutch randomized controlled trial (ZMILE study). BMC Neurol.
14, 255 (2014). doi:10.1186/s12883-014-0255-3
25. Cohen, J.: Statistical power analysis for the behavioral sciences.
L. Erlbaum Associates, Hillsdale (1988)
26. Rosner, B.: Multiple comparisons: Bonferroni approach. Fund.
Biostat 5 (2000)
27. Kazis, L.E., Anderson, J.J., Meenan, R.F.: Effect sizes for
interpreting changes in health status. Med. Care 27(3), S178–
S189 (1989)
28. Angst, F., Verra, M.L., Lehmann, S., Aeschlimann, A.: Respon-
siveness of five condition-specific and generic outcome assess-
ment instruments for chronic pain. BMC Med. Res. Methodol.
8(1), 26 (2008). doi:10.1186/1471-2288-8-26
29. Khan, K.A., Petrou, S., Rivero-Arias, O., Walters, S.J., Boyle,
S.E.: Mapping EQ-5D utility scores from the PedsQLTM generic
core scales. PharmacoEconomics. 32(7), 693–706 (2014). doi:10.
1007/s40273-014-0153-y
30. Tabachnick, B.G., Fidell, L.S., Osterlind, S.J.: Using multivariate
statistics (2001)
31. Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez
Alava, M., Mukuria, C., et al.: Use of generic and condition-
specific measures of health-related quality of life in NICE deci-
sion-making: a systematic review, statistical modelling and sur-
vey. Health Technol. Assess. (Winchester, England) 18(9), 1–224
(2014). doi:10.3310/hta18090
32. Teckle, P., McTaggart-Cowan, H., Van der Hoek, K., Chia, S.,
Melosky, B., Gelmon, K., et al.: Mapping the FACT-G cancer-
specific quality of life instrument to the EQ-5D and SF-6D.
Health Qual. Life Outcomes. 11(1), 203 (2013). doi:10.1186/
1477-7525-11-203
33. Wu, S., Harris, T.J., McAuley, K.B.: The use of simplified or
misspecified models: linear case. Can. J. Chem. Eng. 85(4),
386–398 (2007). doi:10.1002/cjce.5450850401
34. Shmueli, G.: To explain or to predict? Stat. Sci. 289–310 (2010)
A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P…
123
35. Greenberg, E., Parks, R.P.: A predictive approach to model
selection and multicollinearity. J. Appl. Econ. 12(1), 67–75
(1997)
36. Crott, R., Briggs, A.: Mapping the QLQ-C30 quality of life
cancer questionnaire to EQ-5D patient preferences. Eur. J. Health
Econ.: HEPAC Health Econ. Prevent. Care. 11(4), 427–434
(2010). doi:10.1007/s10198-010-0233-7
37. Sullivan, P.W., Ghushchyan, V.: Mapping the EQ-5D index from
the SF-12: US general population preferences in a nationally
representative sample. Med. Decis. Making Int. J. Soc. Med.
Decis. Making. 26(4), 401–409 (2006). doi:10.1177/
0272989x06290496
38. Payakachat, N., Summers, K.H., Pleil, A.M., Murawski, M.M.,
Thomas 3rd, J., Jennings, K., et al.: Predicting EQ-5D utility
scores from the 25-item National Eye Institute Vision Function
Questionnaire (NEI-VFQ 25) in patients with age-related macular
degeneration. Qual. Life Res. Int. J. Qual. Life Aspects Treatment
Care Rehabilitat. 18(7), 801–813 (2009). doi:10.1007/s11136-
009-9499-6
39. Kontodimopoulos, N., Aletras, V.H., Paliouras, D., Niakas, D.:
Mapping the cancer-specific EORTC QLQ-C30 to the prefer-
ence-based EQ-5D, SF-6D, and 15D instruments. Val. Health J.
Int. Soc. Pharmacoecon. Outcomes Res. 12(8), 1151–1157
(2009). doi:10.1111/j.1524-4733.2009.00569.x
40. Dakin, H.: Review of studies mapping from quality of life or
clinical measures to EQ-5D: an online database. Health Qual.
Life Outcomes. 11, 151 (2013). doi:10.1186/1477-7525-11-151
41. McTaggart-Cowan, H.M., Marra, C.A., Yang, Y., Brazier, J.E.,
Kopec, J.A., FitzGerald, J.M., et al.: The validity of generic and
condition-specific preference-based instruments: the ability to
discriminate asthma control status. Qual. Life Res. 17(3),
453–462 (2008). doi:10.1007/s11136-008-9309-6
42. Williams, I., McIver, S., Moore, D., Bryan, S.: The use of eco-
nomic evaluations in NHS decision-making: a review and
empirical investigation. Health Technol. Assess. (Winchester,
England). 12(7), iii, ix–x, 1–175 (2008)
43. Brazier, J., Tsuchiya, A.: Preference-based condition-specific
measures of health: what happens to cross programme compara-
bility? Health Econ. 19(2), 125–129 (2010). doi:10.1002/hec.1580
44. Torrance, G., Keresteci, M., Casey, R., Rosner, A., Ryan, N.,
Breton, M.: Development and initial validation of a new prefer-
ence-based disease-specific health-related quality of life instru-
ment for erectile function. Qual. Life Res. 13(2), 349–359 (2004)
45. Revicki, D.A., Leidy, N.K., Brennan-Diemer, F., Sorensen, S.,
Togias, A.: Integrating patient preferences into health outcomes
assessment: the multiattribute asthma symptom utility index.
Chest 114(4), 998–1007 (1998)
46. Brazier, J., Czoski-Murray, C., Roberts, J., Brown, M., Symonds,
T., Kelleher, C.: Estimation of a preference-based index from a
condition-specific measure: the King’s health questionnaire. Med.
Decis. Making Int. J. Soc. Med. Decis. Making. 28(1), 113–126
(2008). doi:10.1177/0272989x07301820
47. Yang, Y., Tsuchiya, A., Brazier, J., Young, Y. (eds.): Deriving a
preference-based measure for health from the AQLQ. Health
Economists Studying Group Meeting (HESG), London (2006)
48. Donaldson, C., Atkinson, A., Bond, J., Wright, K.: Should
QALYs be programme-specific? J. Health Econ. 7(3), 239–257
(1988). doi:10.1016/0167-6296(88)90027-6
49. Brazier, J.E., Rowen, D., Mavranezouli, I., Tsuchiya, A., Young,
T., Yang, Y, et al.: Developing and testing methods for deriving
preference-based measures of health from condition-specific
measures (and other patient-based measures of outcome). Health
Technol. Assess. (Winchester, England). 16(32), 1–114 (2012).
doi:10.3310/hta16320
B. F. M. Wijnen et al.
123
